These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 21468167)

  • 41. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR
    Wise RA; Calverley PM; Carter K; Clerisme-Beaty E; Metzdorf N; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():605-616. PubMed ID: 29497289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
    Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical equivalence of budesonide dry powder inhaler and pressurized metered dose inhaler.
    Srichana T; Juthong S; Thawithong E; Supaiboonpipat S; Soorapan S
    Clin Respir J; 2016 Jan; 10(1):74-82. PubMed ID: 25043636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis.
    Ram FS; Sestini P
    Thorax; 2003 Jul; 58(7):580-4. PubMed ID: 12832670
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
    Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
    Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First-time handling of different inhalers by chronic obstructive lung disease patients.
    Harb HS; Laz NI; Rabea H; Abdelrahim MEA
    Exp Lung Res; 2020 Sep; 46(7):258-269. PubMed ID: 32614625
    [No Abstract]   [Full Text] [Related]  

  • 48. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.
    Darbà J; Ramírez G; Sicras A; Francoli P; Torvinen S; Sánchez-de la Rosa R
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2335-45. PubMed ID: 26604733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
    Ichinose M; Takizawa A; Izumoto T; Tadayasu Y; Hamilton AL; Kunz C; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1673-83. PubMed ID: 26316741
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a novel digital breath-activated inhaler: Initial particle size characterization and clinical testing.
    Kesten S; Israel E; Li G; Mitchell J; Wise R; Stern T
    Pulm Pharmacol Ther; 2018 Dec; 53():27-32. PubMed ID: 30201410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
    Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
    Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM
    Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
    Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
    Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
    Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute local tolerability of acidic aqueous vehicles delivered via Respimat Soft Mist Inhaler in hyperreactive asthma patients.
    Leclerc V; Lafferre M; Pavia D
    Respiration; 2007; 74(6):691-6. PubMed ID: 17728532
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
    Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
    Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences.
    Ninane V; Vandevoorde J; Cataldo D; Derom E; Liistro G; Munghen E; Peché R; Schlesser M; Verleden G; Vincken W
    Respir Med; 2015 Nov; 109(11):1430-8. PubMed ID: 26439177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
    Henriet AC; Marchand-Adam S; Mankikian J; Diot P
    Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Delivery of fenoterol via Respimat, a novel 'soft mist' inhaler. a randomised, double-blind (within device), placebo-controlled, cross-over, dose-ranging study in asthmatic patients.
    van Noord JA; Smeets JJ; Creemers JP; Greefhorst LP; Dewberry H; Cornelissen PJ
    Respiration; 2000; 67(6):672-8. PubMed ID: 11124651
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
    De Backer W; De Backer J; Verlinden I; Leemans G; Van Holsbeke C; Mignot B; Jenkins M; Griffis D; Ivanov S; Fitzpatrick J; St Rose E; Martin UJ; Reisner C
    Ther Adv Respir Dis; 2020; 14():1753466620916990. PubMed ID: 32380894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.